An RCT of cannabinoid replacement therapy (Sativex®) for the management of treatment-resistant cannabis dependent patients

该项目是有史以来第一个门诊随机对照试验，以测试药物大麻类药物Sativex是否可以安全和具有成本效益地为寻求治疗慢性大麻依赖的患者提供更好的治疗结果。Sativex是一种喷雾剂，含有等量的THC和大麻二酚，似乎比非法大麻或合成THC单独使用具有更安全的药理作用。因此，Sativex可能导致较低的精神不良事件发生率和较高的大麻戒断率。

This project is the first-ever outpatient RCT to test if the pharmaceutical cannabinoid Sativex can safely and cost-effectively deliver better treatment outcomes for patients seeking treatment for chronic cannabis dependence. Sativex is a mouth spray with equal parts THC and cannabidiol, and appears to have a safer pharmacological profile than illicit cannabis or synthetic THC alone. Thus Sativex may lead to lower rates of psychiatric adverse events and increased cannabis abstinence rates.